Humana (HUM) usurped its Q2 earnings projections, driven by Medicare Advantage potency. Both Deutsche Bank and Oppenheimer amplified their PT for the company to $349.00 and $400.00, respectively. Despite this achievement, the company encountered backlash due to the escalation of medical costs, leading to a revision of its yearly outlook. An investor lawsuit against the company is also pending due to alleged securities fraud. Besides,
Q2 2024 earnings call and
shareholder alert announced the impending lawsuit. Greater Boston Partners reduced its HUM stock holdings while Virtu Financial LLC increased its shareholdings. HUMβs
Q2 earnings surpassed estimates, however, concerns about profitability caused the companyβs stocks to plunge due to the increased costs in Medicare Advantage, which was viewed as sub-par. Two assessments forecast Humana Inc. to post Q1 2025 earnings of $9.14 per share. New Centers are being established by HUM's CenterWell in Asheville and Louisiana. The
ASML partnership with Humana, along with an extended partnership with Google, is aiming to decrease cost of care while enhancing member experiences. Despite all this, the company faced a stock tumble, with Class Action Lawsuits seeing the light of day.
Humana HUM News Analytics from Thu, 18 Jan 2024 08:00:00 GMT to Sun, 04 Aug 2024 15:25:00 GMT -
Rating 3
- Innovation 2
- Information 6
- Rumor -4
